Who is sponsoring NCT03518502?

NCT03518502 is sponsored by Korea University.

What drugs are being tested in NCT03518502?

Interventions in NCT03518502: transarterial chemoembolization (TACE), Sorafenib.

What condition does NCT03518502 study?

NCT03518502 studies Hepatocellular Carcinoma, Metastasis.

Is NCT03518502 still recruiting?

NCT03518502 is currently status unknown. Last updated 8 May 2018.

Last reviewed 2018-05-08 · How we verify

NCT03518502

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Sorafenib Monotherapy vs. TACE-sorafenib Sequential Therapy for HCC With Metastasis

Status unknown Phase 4 Last updated 8 May 2018

What this trial tests

Phase 4 trial testing transarterial chemoembolization (TACE) in Hepatocellular Carcinoma in 130 participants. Status unknown.

Timeline

1 March 2012

Primary endpoint
28 February 2020

28 February 2022

Quick facts

Lead sponsor	Korea University
Phase	Phase 4
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	130
Start date	1 March 2012
Primary completion	28 February 2020
Estimated completion	28 February 2022
Sites	6 locations across South Korea

Drugs / interventions tested

transarterial chemoembolization (TACE) — full drug profile →
Sorafenib (SORAFENIB) — full drug profile →

Conditions studied

Hepatocellular Carcinoma — all drugs for Hepatocellular Carcinoma →
Metastasis — all drugs for Metastasis →

Sponsor

Korea University

Who can join

Adults 18 to 75, any sex, with Hepatocellular Carcinoma or Metastasis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Sorafenib is the standard therapy for hepatocellular carcinoma (HCC) with extrahepatic metastasis (EHM). However, addition of transarterial chemoembolization (TACE) may be beneficial for controlling intrahepatic tumour. The investigators aimed to compare the efficacy between the sorafenib monotherapy and TACE-sorafenib sequential therapy in HCC patients with EHM.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Progress on Ras/MAPK Signaling Research and Targeting in Blood and Solid Cancers.
Dillon M, Lopez A, Lin E, Sales D, et al · · 2021 · cited 99× · PMID 34680208 · DOI 10.3390/cancers13205059
The Renaissance of Cyclin Dependent Kinase Inhibitors.
Ettl T, Schulz D, Bauer RJ. · · 2022 · cited 50× · PMID 35053461 · DOI 10.3390/cancers14020293

Verify or expand the search:

Other trials of transarterial chemoembolization (TACE)

Trials testing the same drug.

NCT05213637 — Expanded Activated Lymphocytes (EAL) as Adjuvant Therapy in Patients With HCC at High Risk of Recurrence After Radical R · Phase 2 · unknown
NCT06038552 — Comparison of Clinical Efficacy of Liver Resection, RFA, TACE, and Drug Therapy in Patients with GIST LM · completed

Other recruiting trials for Hepatocellular Carcinoma

Currently open trials in the same condition.

NCT06902246 — Regorafenib and Yttrium-90 Radioembolization for Unresectable Hepatocellular Carcinoma · Phase 2 · recruiting
NCT05842174 — Targeting Ischemia-Induced Autophagy Dependence in Hepatocellular Carcinoma · Phase 1, PHASE2 · recruiting
NCT07417397 — Adjuvant TACE in HCC With High-risk Recurrence Factors · Phase 3 · recruiting
NCT07317414 — β-alanine in the Treatment of Advanced Hepatocellular Carcinoma · Phase 2 · recruiting
NCT07148050 — Immunotherapy for Solid Tumor Malignancies in Pediatrics Using Interleukin-15 and -21 Armored Glypican-3-specific Chimer · Phase 1 · recruiting

Other Korea University trials

Trials by the same sponsor.

NCT07328438 — Diagnosis Disclosure Support for Caregivers of Children With Autism · NA · not yet recruiting
NCT07175701 — Ultra-processed Food-reducing Intervention and Continuous Glucose Monitoring · NA · recruiting
NCT07485387 — Global Collaborative Research on Establishing a Korean Cognitive Aging Cohort · recruiting
NCT06843421 — Korean Health Screening-Based Metabolic Dysfunction-Associated Steatotic Liver Disease Registry · not yet recruiting
NCT06523660 — Improving Executive Function in Korean Children With Autism · NA · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03518502 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Korea University
Last refreshed: 8 May 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03518502.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing